Strong quarterly growth for Hafslund Nycomed
This article was originally published in Clinica
Group revenues at Hafslund Nycomed (Norway) rose 52% to NKr 2,441 million in the first quarter of 1995, compared with NKr 1,608 million in the same period last year. Revenues for Nycomed Imaging, which account for just over half of group turnover, more than doubled to NKr 1,272 million for the first quarter of 1995 compared with NKr 601 million in the same period in 1994.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.